Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: ...

December Global Regulatory Brief: Trading and markets

Bloomberg’s t Global Regulatory Brief reviews recent global regulatory developments, focusing on the EU, US, UK, and Singapore, as they introduce regulations on trading, market structures, and ...

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...
RMD Open

Intraindividual cognitive function course over time in patients with systemic lupus erythematosus

Background Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric systemic lupus ...
AOL

MIT report: 95% of generative AI pilots at companies are failing

Good morning. Companies are betting on AI—yet nearly all enterprise pilots are stuck at the starting line. The GenAI Divide: State of AI in Business 2025, a new report published by MIT’s NANDA ...